Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Novavax Inc NVAX

Healthcare Biotechnology
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID... see more

Recent & Breaking News (NDAQ:NVAX)

Novavax Announces Positive Top-Line Data From RSV F Vaccine Phase 1 Clinical Trial in Pediatrics

GlobeNewswire September 29, 2015

Novavax to Host 3rd Annual Analyst and Investor Meeting

GlobeNewswire September 29, 2015

Novavax to Host 3rd Annual Analyst and Investor Meeting

Thomson Reuters ONE September 29, 2015

Novavax Announces Positive Top-Line Data from Phase 2 Clinical Trial of RSV F Vaccine to Protect Infants via Maternal Immunization

PR Newswire September 29, 2015

Novavax Announces Grant of Up to $89 Million to Support Development of RSV F Vaccine to Protect Infants Via Maternal Immunization

GlobeNewswire September 29, 2015

Novavax Announces Grant of Up to $89 Million to Support Development of RSV F Vaccine to Protect Infants Via Maternal Immunization

Thomson Reuters ONE September 29, 2015

Novavax to Host 3rd Annual Analyst and Investor Meeting

GlobeNewswire September 22, 2015

Novavax to Present at the Ladenburg Thalmann 2015 Healthcare Conference

GlobeNewswire September 21, 2015

Novavax RSV F Vaccine is Highly Immunogenic With Robust Transplacental Antibody Transfer in Preclinical Maternal Immunization Model

Thomson Reuters ONE September 15, 2015

Novavax RSV F Vaccine Clinical Trial Data in Women of Child Bearing Age Published in the Journal of Infectious Disease

Thomson Reuters ONE September 10, 2015

Novavax RSV F Vaccine Clinical Trial Data in Women of Child Bearing Age Published in the Journal of Infectious Disease

GlobeNewswire September 10, 2015

Novavax to Participate in Multiple Investor Conferences in September

Thomson Reuters ONE September 2, 2015

Novavax to Participate in Multiple Investor Conferences in September

GlobeNewswire September 2, 2015

Novavax to Host 3rd Annual Analyst and Investor Meeting

GlobeNewswire August 26, 2015

Novavax Reports Second Quarter 2015 Financial Results

GlobeNewswire August 10, 2015

Novavax Announces Positive Top-Line Data from Phase 2 RSV F-Protein Vaccine Clinical Trial in Older Adults

PR Newswire August 10, 2015

Novavax to Present at the Wedbush PacGrow Healthcare Conference

Thomson Reuters ONE August 5, 2015

Novavax to Present at the Wedbush PacGrow Healthcare Conference

Thomson Reuters ONE August 5, 2015

Novavax to Present at the Wedbush PacGrow Healthcare Conference

GlobeNewswire August 5, 2015

Novavax to Host Conference Call to Discuss Second Quarter Financial Results on August 10, 2015

Thomson Reuters ONE August 3, 2015